Hims & Hers Health stock climbs as price remains inside $18.90

Traders Union
All News
Financial News
Hims & Hers Health rises 3.97% today

Highlights

Hims & Hers Health faces legal investigations and revenue headwinds following the end of its Novo Nordisk partnership and related allegations.
A securities fraud class action lawsuit has been filed, adding legal risk ahead of the company's May 11 earnings release.
Shares trade below major moving averages, with technical signals bearish and expected to remain rangebound between $18.90 and $20.90 amid continued downside pressure.

Legal probes and revenue strain weigh on pre-earnings sentiment

Hims & Hers Health is currently facing ongoing legal investigations and revenue pressure ahead of its first-quarter earnings release scheduled for May 11. The company has experienced challenges following the termination of its partnership with Novo Nordisk in June 2025, after alleged violations related to the mass distribution of compounded medications. A securities fraud class action lawsuit was subsequently filed against the company.

Bearish momentum persists as technical indicators confirm selling bias

Technically, HIMS remains under strong downward pressure as it trades below all major moving averages. The Ichimoku Kijun at $20.93 acts as immediate resistance above the current price. Weak momentum persists, with MACD on daily showing a sell signal and ADX at 24.76 confirming a bearish bias. Daily RSI sits at 43.33 while Stoch RSI (11.68) and CCI (–93.24) indicate oversold conditions. Negative Bull/Bear Power (–1.19) signals continuing seller dominance, though the Awesome Oscillator is neutral. The price currently hovers near the upper end of today's range ($19.58 – $20.23) amid moderate volatility, showing a cautious rebound against a backdrop of bearish momentum signals.

High downside risk prevails as volatility defines weekly outlook

For the coming week, HIMS is expected to fluctuate within a volatility band of $18.90 – $20.90, reflecting recent high volatility and oversold momentum. The probability of further declines remains very high (over 80%), with any upside recovery seen as less likely without a move above resistance at $20.93. The baseline scenario is sideways price action between $18.90 and $20.90, while a break below $18.90 would reinforce selling pressure. A bullish scenario requires a sustained move above $20.93 to signal the possibility of recovery.

Anton Kharitonov, expert at Traders Union, sees strong technical and fundamental headwinds for Hims & Hers Health as it trades below all major moving averages and faces ongoing legal and revenue challenges. He believes bearish momentum dominates, and any upside remains capped by resistance at $20.93. Near-term, the base case is sideways movement, with a risk of further decline below $18.90 if selling pressure builds. "Without a decisive move above $20.93, I do not trust any rebound in HIMS and prefer a defensive stance at these levels."

Earlier, analysts noted that Hims & Hers Health was experiencing sustained bearish momentum with limited prospects for near-term recovery. The latest analysis reinforces this outlook as ongoing legal and revenue headwinds intensify downside risks, making a clear move above $20.93 a critical signal for any potential reversal.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.